Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Senti Biosciences Holdings, Inc. (SNTI) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.33, with a market capitalisation of $9.41M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.29 to $2.88. This page covers its latest market performance, valuation, price trends and company information.
$9.41M | |
$0.30 | |
$87.70 | |
$0.29 | |
$0.30 | |
157.18K | |
253.52K | |
-- | |
$2.88 | |
$0.29 | |
-- | |
-- |
Senti Biosciences Holdings, Inc. (SNTI) is trading at $0.33 in pre-market trading as of 2026-09-16 09:23:00, up 10.00% ($0.03) from the previous close of $0.30
Pre-market trading shows how investors are pricing SNTI before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Senti Biosciences Holdings, Inc. (SNTI) moved from $0.33 to $0.33, representing a decline of 0.78% ($0.00).
The stock traded between $0.29 and $0.36 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 170.63 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.5%
SNTI is currently trading at $0.33, placing it 1.5% of the way from its 52-week low of $0.29 to its 52-week high of $2.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 39 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Senti Biosciences Holdings, Inc. (SNTI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.